NAD+
Analytical results for lot NAD500VAS0126 (10 mL vial), third-party tested by AxisPharm, LLC and reported 2026-02-20.
| Assay | Method | Result |
|---|---|---|
| Purity | HPLC-UV (208 nm) | >99.5% |
| Identity | LC-MS (ESI+) | 665.0 [M+H] |
| Endotoxin | LAL assay | 0.064 EU/mg |
Lot record
| Lot number | NAD500VAS0126 |
|---|---|
| Compound | NAD+ |
| Format | 10 mL vial |
| Label claim | 500 mg |
| Measured content | 511 mg |
| Expected mass | 663.43 g/mol |
| Report date | 2026-02-20 |
| Sample received | 2026-02-17 |
| Manufactured | 2026-01 |
| Best before | 2028-01 |
| Manufacture | GMP-compliant peptide manufacturing facility, United States |
| Third-party analysis | AxisPharm, LLC |
| Status | Current — in stock |
Compound
The central redox cofactor of cellular metabolism and substrate for sirtuins, PARPs, and CD38.
NAD+ specification →Other lots of NAD+
Lot-to-lot comparison across releases.
The certificate for this lot
The results above are published in full. The certificate itself is the testing laboratory’s document, and we supply it per batch rather than as a public download — so a certificate can only ever travel with the material it describes. If you hold or are purchasing lot NAD500VAS0126, request it and we will send it.
Request the certificate for NAD500VAS0126 →All compounds supplied by BioIntegrity Research are intended strictly for laboratory research and educational use. Not for human or animal consumption. Not for diagnostic, therapeutic, or clinical use. No statement on this website has been evaluated by the Food and Drug Administration. Purchaser affirms that products are acquired solely for legitimate laboratory research and assumes full responsibility for lawful handling, storage, and disposal.